Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies (Q35872060)
Jump to navigation
Jump to search
scientific article published on 19 February 2015
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies |
scientific article published on 19 February 2015 |
Statements
1 reference
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies (English)
1 reference
Hagop Kantarjian
1 reference
Srdan Verstovsek
1 reference
Susan O'Brien
1 reference
Farhad Ravandi
1 reference
Gautam Borthakur
1 reference
Jorge E Cortes
1 reference
Guillermo Garcia-Manero
1 reference
Talha Badar
1 reference
19 February 2015
1 reference
1 reference
433-438.e2
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference